BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.
Also called NCT04666454
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,000 participants
- Registry
-
NCT04666454
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark, Norway, Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT04666454. Randomized; no masking; primary purpose treatment. Start 2020-12-14 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
- Condition
- Takotsubo Syndrome
- Intervention (Drug)
- Adenosine
- Intervention (Drug)
- Dipyridamole 200 mg
- Intervention (Drug)
- Apixaban 5 mg Oral Tablet
- Intervention (Other)
- Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
- Lead sponsor
- Vastra Gotaland Region
- Collaborator
- Göteborg University
Record details
- Record id
cardio:ct-nct04666454- Content hash
a08a0e39f0b4ae3ac1e04e34cd10c6088634beedb50cff9f72911c6ea4bbdb95